KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $1.91 $2.71 Friday, 26th Apr 2024 CANF stock ended at $1.98. This is 3.13% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 4.71% from a day low at $1.91 to a day high of $2.00.
90 days $1.91 $2.71
52 weeks $1.71 $3.33

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Mar 04, 2016 $2.46 $2.46 $2.26 $2.43 101 800
Mar 03, 2016 $2.40 $2.52 $2.29 $2.39 243 000
Mar 02, 2016 $2.20 $2.34 $2.18 $2.30 145 100
Mar 01, 2016 $2.13 $2.20 $2.10 $2.16 32 900
Feb 29, 2016 $2.18 $2.19 $2.10 $2.11 58 000
Feb 26, 2016 $2.23 $2.28 $2.13 $2.17 83 300
Feb 25, 2016 $2.12 $2.24 $2.10 $2.22 63 700
Feb 24, 2016 $2.17 $2.26 $2.05 $2.14 63 600
Feb 23, 2016 $2.19 $2.26 $2.13 $2.16 39 100
Feb 22, 2016 $2.33 $2.35 $2.13 $2.21 104 600
Feb 19, 2016 $2.34 $2.34 $2.20 $2.26 44 900
Feb 18, 2016 $2.26 $2.41 $2.25 $2.32 101 100
Feb 17, 2016 $2.06 $2.51 $2.06 $2.28 177 800
Feb 16, 2016 $2.05 $2.15 $2.05 $2.14 58 900
Feb 12, 2016 $1.98 $2.05 $1.96 $2.05 56 900
Feb 11, 2016 $1.95 $2.01 $1.90 $1.95 133 400
Feb 10, 2016 $2.03 $2.08 $1.96 $2.00 69 900
Feb 09, 2016 $2.00 $2.07 $1.95 $2.00 120 200
Feb 08, 2016 $2.15 $2.15 $2.00 $2.04 129 200
Feb 05, 2016 $2.21 $2.21 $2.15 $2.17 71 300
Feb 04, 2016 $2.06 $2.28 $2.06 $2.13 207 600
Feb 03, 2016 $2.13 $2.13 $2.01 $2.08 94 400
Feb 02, 2016 $2.16 $2.20 $2.12 $2.12 46 000
Feb 01, 2016 $2.12 $2.21 $2.11 $2.21 77 900
Jan 29, 2016 $2.17 $2.25 $2.13 $2.20 57 000
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT